Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Last updated refers to the date when our listing for each treatment was last updated.
ID is our internal ID - starting with VT.
Min Karnofsky is a general guide to how well you have to function to use this treatment
For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.

Back to New Treatments List



		Treatment Name:		Phase I Study To Test The Safety of TVAX Immunotherapy As A Treatment For Recurrent Grade III/IV Gliomas

		Keywords:		vaccine, T cells, immunotherapy

		Phase:		Phase 1/2

		Treatment ID#s:		VT1984 NCT01081223

		Age Group:		Adults Only

		Min Karnofsky Score:		70: Cares for self, unable to perform normal activity or to do active work

		Conditions:		Newly Diagnosed: N Recurrent: Y Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed Glioma Glioblastoma Multiforme Astrocytoma Grade III/IV

		Last Updated:		04/12/2010

		Tumor Types:		Anaplastic Astrocytoma Brainstem Glioma Glioblastoma Multiforme Gliosarcoma Mixed Glioma Oligodendroglioma High Grade


		Comments:		TVAX Immunotherapy is an experimental treatment that takes advantage of the fact that your body can produce immune cells, called `killer` white blood cells that have the ability to kill large numbers of the cancer cells that are present in your body. TVAX immunotherapy is designed to generate large numbers of those `killer` white blood cells and to deliver those cells into your body so that they can kill your cancer cells. The TVAX Immunotherapy involves several steps. First, the patient`s cancer must be surgically removed to provide the cells with which to vaccinate the patient and create a cancer-specific immune response. Second, the patient will be vaccinated several times with those cells and an immune system stimulant. Third, the patient`s blood will be filtered for white cells which are then cultured and stimulated to reach a higher (killer) activity level. Fourth, the activated T cells are infused into the patient to attack the cancer.

		Treatment Type:		Immunological, Biological or Targeted Therapy.

		Contact:		TVAX Biomedical Tim Wurst VP Clinical Affairs 8006 Reeder Street Lenexa, KS 66212 Phone:913-492-2221 Click here to send an email Website: www.tvaxbiomedical.com

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2010 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By